{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:46:01Z","timestamp":1760057161195,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M711531"],"award-info":[{"award-number":["2022M711531"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573263"],"award-info":[{"award-number":["81573263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program Key Projects","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515011246"],"award-info":[{"award-number":["2021A1515011246"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013068","name":"Key Technologies Research and Development Program of Guangzhou Municipality","doi-asserted-by":"publisher","award":["202103000077"],"award-info":[{"award-number":["202103000077"]}],"id":[{"id":"10.13039\/501100013068","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118089","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T23:20:28Z","timestamp":1756250428000},"page":"118089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel 3-Benzyloxyaminopyridines as orally available and intracranially active selective ROS1 inhibitors for combating the resistant ROS1G2032R mutation"],"prefix":"10.1016","volume":"300","author":[{"given":"Siming","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zichao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengqiu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanhe","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3510-4040","authenticated-orcid":false,"given":"Jiajie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118089_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00408-020-00407-5","article-title":"Update 2020: management of non-small cell lung cancer","volume":"198","author":"Alexander","year":"2020","journal-title":"Lung"},{"key":"10.1016\/j.ejmech.2025.118089_bib2","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118089_bib3","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ejmech.2025.118089_bib4","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMe1411319","article-title":"ROS1-targeting the one percent in lung cancer","volume":"371","author":"Gold","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118089_bib5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1128\/jvi.42.1.143-152.1982","article-title":"Cellular sequences related to three new onc genes of avian sarcoma virus (fps, yes, and ros) and their expression in normal and transformed cells","volume":"42","author":"Shibuya","year":"1982","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.118089_bib6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gcc.10207","article-title":"Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)","volume":"37","author":"Charest","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejmech.2025.118089_bib7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118089_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","article-title":"ROS1-dependent cancers - biology, diagnostics and therapeutics","volume":"18","author":"Drilon","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118089_bib9","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118089_bib10","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118089_bib11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2016-0101","article-title":"Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.118089_bib12","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118089_bib13","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-21-0032","article-title":"Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion-positive lung cancer","volume":"27","author":"Lin","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118089_bib14","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nec.2020.06.001","article-title":"Epidemiology of brain metastases","volume":"31","author":"Sacks","year":"2020","journal-title":"Neurosurg. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2025.118089_bib15","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118089_bib16","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1097\/JTO.0000000000000468","article-title":"CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment","volume":"10","author":"Metro","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118089_bib17","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-14-1350","article-title":"Molecular changes associated with acquired resistance to crizotinib in ROS1-Rearranged non-small cell lung cancer","volume":"21","author":"Song","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118089_bib18","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1634\/theoncologist.2014-0241","article-title":"FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements","volume":"19","author":"Kazandjian","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.118089_bib19","article-title":"Targeting ALK rearrangements in NSCLC: current state of the art","volume":"12","author":"Peng","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118089_bib20","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118089_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2025.118089_bib22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1158\/1078-0432.CCR-15-1601","article-title":"Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer","volume":"23","author":"Chong","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118089_bib23","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jtho.2018.08.2030","article-title":"Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-Positive non-small cell lung cancer","volume":"14","author":"Sun","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118089_bib24","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK Solvent- front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118089_bib25","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-19-2777","article-title":"Repotrectinib exhibits potent antitumor activity in treatment-na\u00efve and solvent-front-mutant ROS1-Rearranged non-small cell lung cancer","volume":"26","author":"Yun","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118089_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40265-023-01990-6","article-title":"Repotrectinib: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118089_bib27","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118089_bib28","doi-asserted-by":"crossref","first-page":"23729","DOI":"10.18632\/oncotarget.25263","article-title":"Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study","volume":"9","author":"Fujiwara","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118089_bib29","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non-small cell lung cancer: the phase II TRUST-I study","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118089_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128730","article-title":"Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations","volume":"66","author":"Liu","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118089_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41392-021-00841-8","article-title":"Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial","volume":"7","author":"Shi","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118089_bib32","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2159-8290.CD-22-0968","article-title":"NVL-520 is a selective, TRK-Sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118089_bib33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1021\/acs.jcim.7b00019","article-title":"Molecular simulation studies on the binding selectivity of Type-I inhibitors in the complexes with ROS1 versus ALK","volume":"57","author":"Tian","year":"2017","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.118089_bib34","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ejmech.2017.11.002","article-title":"Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors","volume":"143","author":"Tian","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118089_bib35","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/jm401805h","article-title":"Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib","volume":"57","author":"Huang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118089_bib36","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejmech.2019.06.043","article-title":"Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK\/ROS1 dual inhibitors","volume":"179","author":"Liu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118089_bib37","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2227779","article-title":"Discovery of novel 2-aminopyridine derivatives as ROS1 and ALK dual inhibitors to combat drug-resistant mutants including ROS1G2032R and ALKG1202R","volume":"38","author":"Liu","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T15:14:16Z","timestamp":1760022856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S0223523425008542"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118089","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel 3-Benzyloxyaminopyridines as orally available and intracranially active selective ROS1 inhibitors for combating the resistant ROS1G2032R mutation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118089"}}